We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+4.9%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$34M
Cap. Flow
% of AUM
12.86%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DT Midstream
DTM
|
+$1.85M |
| 2 |
Delek US
DK
|
+$898K |
| 3 |
ScottsMiracle-Gro
SMG
|
+$843K |
| 4 |
Valero Energy
VLO
|
+$783K |
| 5 |
FMC
FMC
|
+$709K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COR
Coresite Realty Corporation
COR
|
+$1.67M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
+$551K |
| 4 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
+$448K |
| 5 |
Travere Therapeutics
TVTX
|
+$434K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RXDX
201
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $204K | 0.08% |
5,171
-3,872
| -43% | -$121K |
|
202
Relmada Therapeutics
RLMD
$546M
| $203K | 0.08% |
9,015
+2,312
| +34% | +$51.4K |
|
203
Axsome Therapeutics
AXSM
$12.3B
| $202K | 0.08% |
5,350
+2,204
| +70% | +$81.1K |
|
204
Cytokinetics
CYTK
$10.9B
| $202K | 0.08% |
4,425
-5,298
| -54% | -$204K |
|
205
Syndax Pharmaceuticals
SNDX
$1.82B
| $202K | 0.08% |
9,238
-2,003
| -18% | -$37K |
|
206
Adicet Bio
ACET
$75.3M
| $201K | 0.08% |
+719
| New | +$123K |
|
207
Oric Pharmaceuticals
ORIC
$1.24B
| $201K | 0.08% |
13,677
+2,895
| +27% | +$45.1K |
|
208
Xenon Pharmaceuticals
XENE
$6.36B
| $201K | 0.08% |
6,439
-5,055
| -44% | -$151K |
|
209
Keros Therapeutics
KROS
$202M
| $200K | 0.08% |
3,416
-600
| -15% | -$29.9K |
|
210
TG Therapeutics
TGTX
$8.53B
| $200K | 0.08% |
10,536
+4,987
| +90% | +$129K |
|
|
RAPT
211
DELISTED
RAPT Therapeutics
RAPT
| $198K | 0.07% |
674
+10
| +2% | +$2.67K |
|
212
Roivant Sciences
ROIV
$25B
| $198K | 0.07% |
+19,648
| New | +$163K |
|
213
Nkarta
NKTX
$162M
| $197K | 0.07% |
12,843
+4,922
| +62% | +$84.4K |
|
|
LENZ
214
LENZ Therapeutics
LENZ
$179M
| $197K | 0.07% |
+2,265
| New | +$188K |
|
|
TPTX
215
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $197K | 0.07% |
4,131
+1,396
| +51% | +$62.4K |
|
216
Kymera Therapeutics
KYMR
$9.05B
| $195K | 0.07% |
3,071
-1,134
| -27% | -$66K |
|
217
Xencor
XNCR
$1.47B
| $195K | 0.07% |
4,869
-822
| -14% | -$31.2K |
|
|
IMGN
218
DELISTED
Immunogen Inc
IMGN
| $195K | 0.07% |
26,323
-5,929
| -18% | -$36.8K |
|
|
EPIX
219
DELISTED
ESSA Pharma
EPIX
| $194K | 0.07% |
13,643
+5,817
| +74% | +$64.8K |
|
220
Zentalis Pharmaceuticals
ZNTL
$321M
| $194K | 0.07% |
2,305
-1,489
| -39% | -$115K |
|
|
BCYC
221
Bicycle Therapeutics
BCYC
$276M
| $193K | 0.07% |
3,166
-3,964
| -56% | -$219K |
|
222
Prothena Corp
PRTA
$455M
| $193K | 0.07% |
3,901
-557
| -12% | -$30.9K |
|
223
Fate Therapeutics
FATE
$283M
| $192K | 0.07% |
3,274
+918
| +39% | +$52K |
|
224
Madrigal Pharmaceuticals
MDGL
$12.7B
| $192K | 0.07% |
2,270
+294
| +15% | +$24.2K |
|
225
Crinetics Pharmaceuticals
CRNX
$8.87B
| $191K | 0.07% |
6,726
-4,499
| -40% | -$111K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q4 2021 Portfolio in Review
As of Q4 2021, Virtus ETF Advisers held 421 positions worth $265M, up 17% from $227M the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.
Virtus ETF Advisers deployed $34M of net new capital in Q4 2021, opening 24 new positions and adding to 206 existing holdings. Its largest new stake was Invivyd: 22,625 shares worth $164K.
By sector, the portfolio is most concentrated in Real Estate at 22% of assets, up from 20% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Travere Therapeutics, an estimated $434K trimmed.
- Virtus ETF Advisers's largest Q4 2021 buy was Invivyd: 22,625 shares worth $164K.
- Virtus ETF Advisers added most to DT Midstream in Q4 2021, an estimated $1.85M increase.
- Virtus ETF Advisers's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $434K.
- Virtus ETF Advisers fully exited Coresite Realty Corporation in Q4 2021, selling an estimated $1.67M.
- Virtus ETF Advisers's ten largest holdings make up 9.2% of its $265M portfolio in Q4 2021.
- Virtus ETF Advisers opened 24 new positions and closed 45 in Q4 2021.
- Virtus ETF Advisers's portfolio value rose 17% quarter-over-quarter to $265M.
Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.